Tuesday, August 01, 2023 5:15:02 PM
I really think the better question is, are those who're short NWBO prepared to face a share price which could easily be double or more the current price when it's announced that they've filed for approval with one or more of the regulators?
Those who shorted back when we were selling for $1 or $2 or more may not be hurting that badly, but frankly I can't see why they wouldn't take their profit. Anyone shorted at $1 or less could be in a losing position almost instantly, and I doubt if more than a few days are permitted to cover the short in a squeeze. For those of us who are long, it will be a beautiful thing.
I really don't believe that there is anyone outside of the company who knows how the company intends to do things. Are they waiting to go to all regulators simultaneously? Do they intend to parcel out the good news over a number of weeks, or months to keep NWBO's name in the press over several weeks of months? I certainly believe that any of this is possible, I have no idea what management has in mind.
Gary
Those who shorted back when we were selling for $1 or $2 or more may not be hurting that badly, but frankly I can't see why they wouldn't take their profit. Anyone shorted at $1 or less could be in a losing position almost instantly, and I doubt if more than a few days are permitted to cover the short in a squeeze. For those of us who are long, it will be a beautiful thing.
I really don't believe that there is anyone outside of the company who knows how the company intends to do things. Are they waiting to go to all regulators simultaneously? Do they intend to parcel out the good news over a number of weeks, or months to keep NWBO's name in the press over several weeks of months? I certainly believe that any of this is possible, I have no idea what management has in mind.
Gary
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
